PriceTargets.com logo

Sernova - SVA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$1.83
  • Forecasted Upside: 697.10%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
C$0.23 As of 12/17/2024 01:00 AM ET
▲ +0.01 (4.55%)

This chart shows the closing price for SVA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sernova Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SVA

Analyst Price Target is C$1.83
▲ +697.10% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Sernova in the last 3 months. The average price target is C$1.83, with a high forecast of C$2.50 and a low forecast of C$1.50. The average price target represents a 697.10% upside from the last price of C$0.23.

This chart shows the closing price for SVA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Sernova. This rating has held steady since August 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2024

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/13/2024Ventum FinancialLower TargetBuyC$3.00 ➝ C$2.50
9/13/2024Leede FinancialLower TargetSpeculative BuyC$3.00 ➝ C$1.50
9/12/2024Ventum Cap MktsUpgradeStrong-Buy
4/4/2024Raymond JamesSet TargetMarket PerformC$1.50
3/8/2023HC WainwrightReiterated RatingBuyC$6.00
1/10/2023HC WainwrightReiterated RatingBuyC$6.00
11/18/2022HC WainwrightReiterated RatingBuyC$6.00
9/20/2022Roth CapitalReiterated RatingBuy
7/11/2022HC WainwrightInitiated CoverageBuyC$6.00
7/5/2022HC WainwrightSet TargetBuyC$6.00
7/5/2022HC WainwrightReiterated RatingBuyC$6.00
5/17/2022Echelon Wealth PartnersReiterated RatingBuyC$3.75
2/9/2022Echelon Wealth PartnersReiterated RatingSpeculative Buy
2/9/2022Echelon Wealth PartnersInitiated CoverageBuyC$3.25
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 3 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 5 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/17/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Sernova logo
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.
Read More

Today's Range

Now: C$0.23
Low: C$0.22
High: C$0.24

50 Day Range

MA: C$0.24
Low: C$0.22
High: C$0.27

52 Week Range

Now: C$0.23
Low: C$0.20
High: C$0.73

Volume

210,425 shs

Average Volume

160,693 shs

Market Capitalization

C$74.82 million

P/E Ratio

N/A

Dividend Yield

7.86%

Beta

1.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Sernova?

The following Wall Street sell-side analysts have issued stock ratings on Sernova in the last year: Leede Financial, Raymond James, Ventum Cap Mkts, and Ventum Financial.
View the latest analyst ratings for SVA.

What is the current price target for Sernova?

0 Wall Street analysts have set twelve-month price targets for Sernova in the last year. Their average twelve-month price target is C$1.83, suggesting a possible upside of 697.1%. Ventum Financial has the highest price target set, predicting SVA will reach C$2.50 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of C$1.50 for Sernova in the next year.
View the latest price targets for SVA.

What is the current consensus analyst rating for Sernova?

Sernova currently has 1 hold rating, 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SVA will outperform the market and that investors should add to their positions of Sernova.
View the latest ratings for SVA.

What other companies compete with Sernova?

Other companies that are similar to Sernova include VIVO Cannabis, Emblem, Fennec Pharmaceuticals, BriaCell Therapeutics and ImmunoPrecise Antibodies. Learn More about companies similar to Sernova.

How do I contact Sernova's investor relations team?

Sernova's physical mailing address is No. 15 Zhi Tong Road,, Beijing, Beijing 102200. The company's listed phone number is 861082890088. The official website for Sernova is www.sinovacbio.com. Learn More about contacing Sernova investor relations.